To determine the ability of antibodies to provide protection from Ebola vir
uses, monoclonal antibodies (mAbs) to the Ebola glycoprotein were generated
and evaluated for efficacy. We identified several protective mAbs directed
toward five unique epitopes on Ebola glycoprotein. One of the epitopes is
conserved among all Ebola viruses that are known to be pathogenic for human
s. Some protective mAbs were also effective therapeutically when administer
ed to mice 2 days after exposure to Lethal Ebola virus. The identification
of protective mAbs has important implications for developing vaccines and t
herapies for Ebola virus.